LKT Labs

Biochemicals for Life Science Research

Dabrafenib

Dabrafenib

Product ID D0004
Cas No. 1195765-45-7
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $55.10 In stock
25 mg $148.90 In stock
100 mg $529.20 In stock
Bulk Quote

Quicklinks

Description

Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.

Product Info

Cas No.

1195765-45-7
Purity

≥98%
Formula

C23H20F3N5O2S2
Formula Wt.

519.56
IUPAC Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
Synonym

GSK2118436A
Solubility

soluble in DSMO
Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D0004 MSDS PDF
Info Sheet

D0004 Info Sheet PDF
Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T3324

    Tigecycline

    Glycylcycline; protein synthesis inhibitor.
    ≥98%
  • R5212

    RN-486

    Btk inhibitor.
    ≥98%
  • H0100

    Hemagglutinin-1 Peptide

    Peptide, hemagglutinin epitope.
    ≥95%
  • A3212

    3′-Azido-3′-deoxythymidine

    Nucleoside (thymidine) analog; DNA chain terminato...
    ≥98%
  • G6400

    Glycylglutamine

    Endogenous dipeptide, beta-endorphin derivative.
    ≥95%
  • S0344

    Salermide

    SIRT inhibitor.
    ≥98%
  • L5624

    Loganin

    Iridoid glucoside found in Cornus officialis; β-s...
    ≥98%
  • B6808

    [Des-Pro2]-Bradykinin

    Natriuretic, vasodilatory peptide, bradykinin anal...
    ≥95%
  • R8206

    Rubescensin A

    Diterpene originally found in Rabdosia.
    ≥93%
  • L0107

    Lactacystin

    Found in Streptomyces; proteasome inhibitor.
    ≥98%
  • I7357

    Isorhamnetin

    Flavonol found in Tagetes.
    ≥98%
  • V7200

    VS-5584

    PI3K inhibitor.
    ≥98%
  • T286165

    Theaflavin-3-gallate

    Polyphenolic compound present in black tea.
    ≥95%
  • S182680

    SER 601

    Cannabinoid receptor 2 selective agonist.
    ≥98%
  • L1661

    Leptin (116-130), mouse

    Endogenous peptide fragment, involved in feeding b...
    ≥95%
  • T5871

    Torin 2

    Tricyclic benzonaphthyridinone; mTORC1/2 inhibitor...
    ≥98%
  • L2876

    Luteinizing Hormone Releasing Hormone III, lamprey

    Peptide hormone found in eels; GnRH agonist, weak ...
    ≥98%
  • S8147

    Sulindac Sulfide

    NSAID; COX-1/2 and PDE inhibitor.
    ≥98%
  • R2811

    Recombinant HIV-1 gp-41

    Recombinant HIV glycoprotein antigen fragment.
    ≥95%
  • D3200

    Diacetoxyscirpenol

    Type A trichothecene mycotoxin produced by Fusariu...
    ≥98%